Industry Pharmacists, Regulation, and Free Speech

January 23, 2013

In theory, a recent decision by the Second Circuit Court of Appeals may change the way that pharmaceutical manufacturers promote their products. The court sided with a sales representative’s right to free speech when communicating with physicians. This result has raised some very interesting questions about FDA’s regulation of “off-label” information.

About the Author
Jack Bradley, PharmD, JD
Jack Bradley is a pharmacist and an attorney possessing more than 20 years of experience in the pharmaceutical sector. Following a post-doctoral fellowship at Warner-Lambert/Parke-Davis, Jack has enjoyed a rewarding career in the pharmaceutical industry, holding roles of increasing responsibility within sanofi-aventis and Schering-Plough/Merck. Presently, Jack is the Medical Director for North America for Sobi, Inc., a Stockholm-based company dedicated to finding cures for rare diseases.

This content is only available for guests of the site.

Please create a guest account below. Already registered? Log in now!

Create a guest account
Login to your account